Basic Cancer Info

The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The agent Zykadia (ceritinib), a "second generation" ALK inhibitor that is more effective than Xalkori (crizotinib) in lab models of ALK-positive NSCLC, and the new approval was for Zykadia as first line treatment for ALK-positive lung cancer, a setting where we have historically favored Xalkori since it was approved in 2011. .

1. Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss molecular marker testing for advanced NSCLC for Spanish speaking patients and caregivers.

GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance. Dr. Santana-Davila joined GRACE to discuss the different types of lung cancer.

GRACE is pleased to welcome Dr. Rafael Santana-Davila, Assistant Professor with the University of Washington School of Medicine and Seattle Cancer Care Alliance. Dr. Santana-Davila joined GRACE to discuss the basics of lung cancer staging.

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss molecular marker testing for advanced NSCLC.

On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. Our last presentation discusses supportive care for patients, with Amber Procter, PharmD, and Jason Akulian, MD.

On November 4th, 2016, in collaboration with UNC Lineberger and Lung Cancer Initiative of NC, GRACE presented 'Not Your Father's Squamous Lung Cancer'. Our third presentation discusses future directions in treatment, with Chad Pecot, MD.